DEF 14A: Y-mAbs Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Y-mAbs Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, to vote on director elections, auditor ratification, and executive compensation.

Summary

• Y-mAbs Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, at 8:00 a.m. Eastern Time, in a virtual format.
• Stockholders of record as of April 19, 2024, are entitled to vote.
• The meeting will address the election of three Class III directors (Michael Rossi, Thomas Gad, and Johan Wedell-Wedellsborg) to serve until the 2027 annual meeting.
• Stockholders will also vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• A non-binding advisory vote on the compensation of the company's named executive officers will also take place.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of PricewaterhouseCoopers LLP, and FOR the approval of executive compensation.
• The company has engaged D.F. King for proxy solicitation services at an anticipated cost of approximately $12,500.
• Dr. Grard Ber will resign from the Board of Directors effective June 10, 2024, reducing the board size from nine to eight members.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the routine nature of the business and the board's recommendations, while the resignation of a board member is a slightly negative factor.

Positives

• The Board of Directors is actively engaged in corporate governance and oversight.
• Stockholders have multiple avenues to vote, including online, by phone, and by mail.
• The company is committed to transparency and providing stockholders with necessary information.
• The Board recommends voting FOR all proposals.

Negatives

• Dr. Ber will resign from the Board of Directors effective June 10, 2024.

Risks

• Failure to secure a quorum could lead to adjournment of the meeting.
• A significant vote against executive compensation could necessitate a review of compensation policies.
• The virtual format may present technical difficulties for some stockholders.

Future Outlook

The document outlines the business to be conducted at the Annual Meeting and does not provide specific forward-looking statements about the company's financial performance or strategic direction beyond the meeting itself.

Management Comments

• 'Thank you for your ongoing support and continued interest in the Company. We look forward to receiving your vote in respect of the business to be conducted at the Annual Meeting,' said Michael Rossi, President and Chief Executive Officer.

Industry Context

The document is a standard proxy statement related to corporate governance matters and does not provide specific insights into broader industry trends or competitive dynamics.

Management Changes

Stakeholder Impact

• The outcome of the votes will impact the composition of the Board of Directors and the oversight of the company.
• The advisory vote on executive compensation provides stockholders with a voice on executive pay practices.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 11, 2024, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, Y-mAbs Therapeutics